Author Archives: Margarida Maia

PROOF-HD Phase 3 Pridopidine Trial Reaches 25% Enrollment

Prilenia Therapeutics has enrolled more than 120 patients in PROOF-HD, a Phase 3 clinical trial investigating the efficacy and safety of oral pridopidine in early stage Huntington’s disease. That amounts to 25% of the target enrollment of up to 480 patients, the company announced. The trial is…